As we reported in our Marijuana Reclassification news article of January 23rd, a federal appellate court ruled that marijuana would remain a Schedule 1 drug, defined as having no accepted medial value and a high potential for abuse.
The court deferred to the judgement of federal autorities and quoted the DEA’s statement that “the effectivness of a drug must be established in well-controlled, well-designed, well-conducted and well documented scientific studies.” According to this article in the Los Angeles Times, to date, such studies have not been performed. According to the article, the DEA via its own ultra-tight restrictions has made it nearly impossible for such studies to be conducted.
This in our opinion constitutes a “Catch 420.” Of further confusion is U.S. Patent Number 6630507 (an abstract of which can be found here) issued to: The United States of America as represented by the Department of Health and Human Services for “Cannabinoids as having been found to have antioxidant properties” “Useful in the treatment of… neurodegenerative diseases such as Alzheimer’s, Parkinson’s and HIV dementia… Huh? While spending billions to promote and anti-drug policy, the US also went about trying to prove the theraputic benefits of cannabinoids.
Connect